Granahan Investment Management LLC Grows Stake in Taysha Gene Therapies, Inc. $TSHA

Granahan Investment Management LLC grew its stake in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) by 16.5% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 1,116,629 shares of the company’s stock after acquiring an additional 158,136 shares during the period. Granahan Investment Management LLC owned about 0.41% of Taysha Gene Therapies worth $3,651,000 at the end of the most recent reporting period.

A number of other hedge funds also recently modified their holdings of TSHA. Vanguard Group Inc. lifted its stake in Taysha Gene Therapies by 17.9% in the third quarter. Vanguard Group Inc. now owns 12,849,613 shares of the company’s stock valued at $42,018,000 after purchasing an additional 1,955,486 shares during the last quarter. Octagon Capital Advisors LP increased its position in Taysha Gene Therapies by 17.7% in the second quarter. Octagon Capital Advisors LP now owns 12,592,500 shares of the company’s stock worth $29,089,000 after buying an additional 1,892,500 shares during the last quarter. Jefferies Financial Group Inc. raised its stake in shares of Taysha Gene Therapies by 4,105.3% in the second quarter. Jefferies Financial Group Inc. now owns 10,313,733 shares of the company’s stock valued at $23,825,000 after buying an additional 10,068,479 shares during the period. Barclays PLC raised its stake in shares of Taysha Gene Therapies by 1,042.8% in the third quarter. Barclays PLC now owns 5,148,112 shares of the company’s stock valued at $16,834,000 after buying an additional 4,697,611 shares during the period. Finally, Adage Capital Partners GP L.L.C. purchased a new position in shares of Taysha Gene Therapies during the 2nd quarter valued at $11,178,000. Institutional investors own 77.70% of the company’s stock.

Taysha Gene Therapies Stock Performance

NASDAQ:TSHA opened at $4.53 on Tuesday. The business’s fifty day moving average is $4.69 and its 200 day moving average is $4.52. The firm has a market cap of $1.24 billion, a price-to-earnings ratio of -13.73 and a beta of 1.02. The company has a debt-to-equity ratio of 0.23, a quick ratio of 10.48 and a current ratio of 10.48. Taysha Gene Therapies, Inc. has a 52-week low of $1.05 and a 52-week high of $6.02.

Insider Activity

In other news, insider Sukumar Nagendran sold 26,918 shares of the firm’s stock in a transaction that occurred on Monday, January 26th. The shares were sold at an average price of $4.61, for a total value of $124,091.98. Following the completion of the transaction, the insider directly owned 1,317,389 shares in the company, valued at approximately $6,073,163.29. This trade represents a 2.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Kamran Alam sold 23,849 shares of the business’s stock in a transaction that occurred on Monday, January 26th. The shares were sold at an average price of $4.61, for a total transaction of $109,943.89. Following the transaction, the chief financial officer directly owned 1,443,786 shares of the company’s stock, valued at approximately $6,655,853.46. This represents a 1.62% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 598,623 shares of company stock worth $2,822,188 over the last ninety days. Company insiders own 3.78% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on TSHA. The Goldman Sachs Group set a $11.00 price objective on Taysha Gene Therapies in a research note on Thursday, December 4th. Raymond James Financial reiterated a “strong-buy” rating and set a $13.00 target price on shares of Taysha Gene Therapies in a research report on Tuesday, January 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Taysha Gene Therapies in a research report on Monday, December 29th. Chardan Capital reiterated a “buy” rating and issued a $12.00 target price on shares of Taysha Gene Therapies in a research note on Tuesday, January 6th. Finally, Wall Street Zen cut shares of Taysha Gene Therapies from a “hold” rating to a “sell” rating in a research note on Saturday, January 3rd. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Taysha Gene Therapies currently has a consensus rating of “Moderate Buy” and a consensus price target of $10.91.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.